Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average...
New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes Allurion Technologies...
Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief...
Company also announces first commercial agreements for the Virtual Care Suite in the United States Allurion Technologies, Inc. (NYSE: ALUR), a...
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming...
New data demonstrate significant fat mass loss while preserving lean mass Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial...
New data demonstrates 80% sustained weight loss at three years with the Allurion Program and initial positive outcomes of a novel, generative...
Generated quarter-over-quarter revenue growth and continued growth in procedural volume, while substantially reducing cash burn Company to report...
Simplifies capital structure through prepayment of existing term loan Reduces annual interest expense, providing increased near-term cash flow...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.